Elizabeth Trice Loggers, MD, PhD
Group Health Physician, Oncology
Research interests and experience
- End-of-life care: quality of care; communication; racial disparities
- Cancer control: quality of life; health outcomes; end-of-life care; participation in clinical trials; Hispanic acculturation and cancer outcomes; geriatrics; patient/provider interaction
- Health services & economics: primary care delivery and cancer outcomes; intensity and cost of care; comparative effectiveness analyses
- Rare cancers: treatment variability and outcomes; end-of-life care
Elizabeth Trice Loggers joined Group Health Research Institute in 2009 after completing a fellowship in the Department of Medical Oncology at the Dana-Farber Cancer Institute (DFCI). Her research while at the Center for Psycho-oncology and Palliative Care Research at DFCI focused primarily on communication and end-of-life care for advanced cancer patients, with an emphasis on racial and ethnic differences. Her position as assistant investigator is a joint appointment with the Clinical Research Division of Fred Hutchinson Cancer Research Center. Dr. Loggers maintains a part-time clinical practice at Seattle Cancer Care Alliance where she specializes in the treatment of individuals with sarcoma (i.e., cancers of the bone, muscles, nerves, or vessels) and is the Medical Director for Palliative Care.
Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, Aiello Bowles EJ, Menter A, Loggers ET, Ritzwoller D. Factors associated with first-line bevacizumab use in advanced, non-squamous, non-small cell lung cancer. J Cancer Res Ther. 2014;2(1):1-8.
Henrikson N, Tuzzio L, Loggers ET, Miyoshi J, Buist DS. Patient and oncologist discussions about cancer care costs. Support Care Cancer. 2013 Nov 26. [Epub ahead of print]. PubMed
Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, Aiello Bowles EJ, Elston-Lafata J, Hornbrook MC. Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care. 2013 Oct;51(10):e67-73. doi: 10.1097/MLR.0b013e31824def85. Epub 2012 Apr 23. PubMed
Loggers ET, Maciejewski PK, Jimenez R, Nilsson M, Paulk E, Stieglitz H, Prigerson HG. Predictors of intensive end-of-life and hospice care in Latino and white advanced cancer patients. J Palliat Med. 2013 Oct;16(10):1249-54. doi: 10.1089/jpm.2013.0164. Epub 2013 Sep 20. PubMed
Chang AE, Mann GN, Hoch B, Loggers ET, Pollack SM, Kolokythas O, Jones RL. Multiple liver abscess formation and primary gastrointestinal stromal tumor. Rare Tumors. 2013 Sep 4;5(3):e51. doi: 10.4081/rt.2013.e51. PubMed
Gold LS, Buist DS, Loggers ET, Etzioni R, Kessler L, Ramsey SD, Sullivan SD. Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington State. J Oncol Pract. 2013 Sep;9(5):e194-202. doi:10.1200/JOP.2012.000796. Epub 2013 May 28. PubMed
Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun;30(2):501. doi: 10.1007/s12032-013-0501-3. Epub 2013 Feb 28. PubMed
Loggers ET, Starks H, Shannon-Dudley M, Back AL, Appelbaum FR, Stewart FM. Implementing a Death with Dignity program at a comprehensive cancer center. N Engl J Med. 2013 Apr 11;368(15):1417-24. doi: 10.1056/NEJMsa1213398. PubMed
Calip GS, Boudreau DM, Loggers ET. Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment. Breast Cancer Res Treat. 2013 Feb;138(1):225-33. doi: 10.1007/s10549-013-2424-2. Epub 2013 Jan 29. PubMed
Spangler L, Yu O, Loggers E, Boudreau DM. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Womens Health (Larchmt). 2013 Feb;22(2):132-40. doi: 10.1089/jwh.2012.3687. Epub 2013 Jan 30. PubMed
Constantinidou A, Pollack S, Loggers ET, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23. PubMedTo view more publications, please see Dr. Logger’s CV.